Hottuna & aatisket All good points about the Japan market and...

Hottuna & aatisket
All good points about the Japan market and msb looking for Japan deals. A streamlined approvals process from the over-the-top US. And looking towards Japanese partnerships, trials and sales. A positive that there is an "easier" scheme for commercialisation & trial of stem cell therapies in such a major economy.
Some caution though. Another poster suggested msb have about 5 mos.(?) cash and Japan "deals" can take a long time to secure actual signed agreements. And that is before a Japanese partner actually delivers a significant funds, sales or otherwise. Especially in the absence of what a Japan partner considers suitable efficacy.

Hoping msb are more successful than rgs who have been spruiking Japan partnership deal "discussions" over the past year to try and support their SP. Failing 3 QTRs so far to secure a deal of any kind. Each time repeating similar "discussions" & "deal end of next quarter". Now < 2 mos cash and desperation cap raise upcoming. Granted all-msb are not rgs.

Japan is certainly an msb opportunity, but not unwise to have some caution about "discussions" and actual delivery of transformative deals in the short term. GLTAH.